Primary and secondary outcome measures: Immunoexpressions of EMP2 were analyzed and the outcomes were correlated with clinicopathological features and patient survivals.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is an endemic head and neck epithelial malignancy in Southeastern Asia and Taiwan, strongly linked to EpsteineBarr virus (EBV). 1e3 The latter association is especially authentic for the differentiated and undifferentiated non-keratinising carcinoma types, according to current WHO tumour classification, although genetic and environmental factors also play certain roles in pathogenesis. 1 2 4 The advances in diagnostic imaging, radiation therapy and adjuvant chemotherapy of NPC have achieved better locoregional control, while it appears less satisfactory in final treatment outcomes. 5 6 Even though being an important parameter, Tumour, Node, Metastasis staging still has space to improve in terms of providing the optimal prognostication to the patients. 1 5 7 Therefore, to identify potential biomarkers with better correlation to tumour growth and/or treatment outcomes in patients with NPC, subsequently, to aid in risk stratification and perhaps development of therapeutic targets, are indispensable. Strengths and limitations of this study -Significant correlation between loss of EMP2 expression and several clinicopathologic variables supported its potential role in nasopharyngeal carcinomas. -The molecular mechanisms underlying EMP2 action require to be elucidated.
Human epithelial membrane protein-2 gene (EMP2), mapped to chromosome 16, is highly conserved across vertebrates. 8e10 The expression pattern of EMP2 partially overlaps to that of the peripheral myelin protein 22 (PMP22, also known as the growth arrest-specific-3, GAS3) transcript. By containing the claudin domain and sharing approximately 40% amino acid identity with PMP22/GAS3, 11 the EMP2 protein was detected as a novel member of this four-transmembrane (tetraspan) superfamily. 12 In humans, EMP2 has a discrete cell type and tissue distribution, with high levels observed in the lung and moderate levels in the eye, heart, thyroid, uterus and intestine. 11 13 14 Functionally, the best understood tetraspan proteins are connexins, which form the major structural element of gap junctions. Connexins play important roles in the regulation of cell growth and differentiation. Cancer cells usually have downregulated levels of gap junctions, and several lines of evidence suggest that loss of gap junctional intercellular communication is an important step in carcinogenesis. Re-expression of connexins in cancer cells causes normalisation of cell growth control and reduced tumour growth. 15 Accordingly, we aimed to systematically analyse EMP2 immunoexpression in patients with NPC and identified that loss of EMP2 expression is associated with adverse prognosticators, conferring to poor survivals.
MATERIALS AND METHODS Patients and tumour specimens
The institutional review board approved the study by using formalin-fixed tissue of NPC for this study (IRB100-09-003). Available paraffin-embedded tissue blocks were retrieved from 124 NPC patients who underwent biopsy between January 1993 and December 2002. These patients were free of distant metastasis at initial presentation. The histological subtypes were reappraised according to the current WHO classification and, the tumour staging was re-evaluated with the 7th American Joint Committee on Cancer (AJCC) system by two pathologists, independently.
Immunohistochemical staining and assessment of EMP2 expression Tissue sections of 3 mm thickness were cut onto precoated slides from paraffin-embedded tissue blocks and were next routinely deparaffinized with xylene and rehydrated with ethanol washes. Slides were heated by the microwave in a 10 mM citrate buffer (pH 6.0) for 7 min to retrieve antigens. Endogenous peroxidase was blocked with 3% H 2 O 2 . Slides were next washed by Trisbuffered saline for 15 min and subsequently incubated with a rabbit polyclonal primary antibody targeting EMP2 (Atlas Antibodies, Stockholm, Sweden) at a dilution of 1:75 for 1 h. Primary antibodies were detected using the DAKO ChemMate EnVision Kit (K5001, Carpinteria, California, USA). The slides were incubated and developed with the secondary antibody for 30 min and 3,3-diaminobenzidine for 5 min, followed by counterstained using Gill's haematoxylin. Immunoexpression of EMP2 was scored by two pathologists (C-FL and H-YH) using a multiheaded microscope to reach a consensus for each case without prior knowledge of clinical and follow-up information. The percentage of tumour cells with EMP2 immunoexpression was recorded for each specimen and loss of EMP2 expression (negative) was defined in cases with staining #5% tumour cells (see the Statistical analysis section).
Treatment and follow-up
All 124 patients with follow-up for outcome have received complete course of radiotherapy (RT, total dose $7000 cGy) and also cisplatin-based chemotherapy in those of stage IIeIV diseases, based on the previously published protocol. 16 The method of RT was in general uniform within this period. All patients were regularly monitored after RT until death or their last appointment with the mean follow-up duration being 59.6 months (range: 4e117).
Statistical analysis
Statistics were performed using SPSS V.14.0 software (SPSS Inc). c 2 Test was used to compare the EMP2 expression status and various clinicopathological parameters. The end points analysed were diseasespecific survival (DSS) and local recurrence-free survival (LRFS), calculated from the starting date of RT to the figure 1A ) or non-tumour epithelium with squamous metaplasia (figure 1B) could be appreciated in 71 samples and all showed intense EMP2 immunoexpression. A wide range of stained tumour cell, characterised by cytoplasmic and/or membranous staining, varying from 0% to 90% (median, 30%) were detected in tumour elements. Of these, 63 cases showed characteristic EMP2 staining (>5% tumour cells; figure 1C ), while 61 cases were <5% staining and therefore classified as EMP2 negative ( figure 1D ). Loss of EMP2 expression was significantly associated with cases featuring increment of primary tumour (p¼0.004), nodal status (p¼0.045) and AJCC stage (p¼0.027) (table 2) . However, no significant association between the EMP2 expression level and other clinicopathological factor was found.
Prognostic impact of EMP2 expression in NPC
Patients with NPC more frequently progressed to disease-specific mortality with N2eN3 nodal status (p¼0.002) and stages IIIeIV (p¼0.007) (table 3) . Besides, patients with advanced AJCC stages IIIeIV held shorter DSS (p¼0.07; figure 2A ) and LRFS (p¼0.06; figure 2B ). The development of local recurrence was significantly associated with T3eT4 (p¼0.027), N2eN3 status (p¼0.023) and AJCC stages IIIeIV (p¼0.005) with a medium duration of 24 months (table 3) . Of note, EMP2 negative correlated to a more aggressive clinical course with a significantly shorter DSS (p¼0.002; figure 2C ) and LRFS (p¼0.005; figure 2D ) in patients with NPC. In multivariate analysis ( 
DISCUSSION
Loss of EMP2 immunostaining as one potent prognosticator for both DSS and LRFS in a subset of patients with NPC was sustained in this study. Intriguingly, we have also identified a significant association between loss of EMP2 expression and the overexpression of latent membrane protein 1 (p¼0.007, data not shown), an important oncoprotein of EBV, 17 suggesting a potential role of EMP2 loss in EBV-associated tumour progression.
However, significantly high EMP2 expression was found in ovarian cancer through activation of caveolins/glycosylphosphatidyl inositol-linked proteins 18 and was identified as an early predictor of endometrial cancers with unfavourable outcome. 19 Due to non-neoplastic peritoneal, surface tissues were complete negative for EMP2 staining, thus EMP2 was regarded as increased expression in tumour cells in ovarian cancer. 20 Moderately intense diffuse immunohistochemical stainings of tumour cell cytoplasm were identified in endometrioid adenocarcinoma, serous carcinoma, mixed endometrioid and serous carcinoma, mixed endometrioid and clear cell carcinoma. 21 On the other hand, compared with undifferentiated ones, predominant expressions of EMP2 in cytoplasm and/or membrane of squamous metaplasias and non-keratinising NPCs were found in our study, suggesting that loss of EMP2 expression might change its interactions with some membrane proteins in NPC. Surface expression of the a6b1 integrin was specifically increased by EMP2 in NIH3T3 fibroblasts. 22 Moreover, surface expression and trafficking of integrin 25 Endocytosis and recycling are crucial in the regulation of integrin turnover and redistribution in adherent cells, especially during dynamic processes such as migration and invasion. 26 Therefore, EMP2 probably plays a tumour suppressor role through interacting with specific integrin(s) in epithelial cells and, thereafter, manages regular signalling transduction in benign conditions.
In addition to the above finding, we uncovered that ectopic expression of EMP2 in a malignant human urothelial cell line, J82, significantly reduced cell proliferation, cell cycle progression, migration and invasion in vitro (unpublished). Consistently, suppression subtractive hybridisation technologies isolated mouse orthologue Emp2, which suppresses B cell lymphoma tumorigenicity through a functional tumour suppressor phenotype. 10 The susceptibility to allogeneic cytotoxic T lymphocytes of a mouse malignant, Emp2-deficient cell line (MV) 10 has been enhanced by retroviral overexpression of Emp2 gene. 27 Constitutive overexpression of EMP2 or other epithelial membrane proteins including EMP1, EMP3 and PMP22, in human HEK293 epithelial cells, leading to the development of apoptotic phenotypes, were demonstrated by purinergic receptor P2X, ligandgated ion channel, 7 (P2RX7)-mediated cell blebbing, annexin V binding to plasma membrane and cell death, through a caspase-dependent pathway. Physically, the C-terminal domain of P2RX7 protein associates with EMPs and mediates some aspects of the downstream signalling following P2RX7 activation. 28 All these studies supported our clinical observations, reinforcing that EMP2 might play distinct characteristics in different cellular contexts. Indeed, the aetiology of NPC is complex, including a host of viral, genetic and environmental factors. 3 29 30 In spite of cure for the majority of the patients, challenges still exist in the prevention of disease relapse and treatment of patients with refractory or metastatic NPC.
31e33 Therefore, for the first time, loss of EMP2 expression was identified as a biomarker independently correlated with tumour aggression to facilitate appropriate allocation of adjuvant therapy, suggesting its significance for patient-tailored strategy to manage high-risk NPCs.
Except for loss of EMP2 expression, significantly increased HRs of DSS and LRFS in NPC patients with higher stages (IIIeIV) were further ascertained, analogous to other studies. 34e36 Additionally, we revealed significant correlations between loss of EMP2 expression and primary tumour, nodal status and stage in NPCs, indicating its prospective role in preventing NPC progression and aggressiveness. Although the precise characteristics of the EMP2 protein in NPC progression remain to be elucidated, the potential utility of EMP2 immunostaining as a prognostic biomarker in NPCs is assured.
